AI specialist Exscientia signs drug discovery tie-up with BayerUK artificial intelligence company Exscientia has added another big pharma company to its partner roster, with Bayer seeking Share XAI specialist Exscientia signs drug discovery tie-up with Bayerhttps://pharmaphorum.com/news/ai-specialist-exscientia-signs-drug-discovery-tie-up-with-bayer/
Apple launches Research app, along with three health studiesApple has launched its Research app – first promised in September – that allows users of its iPhone Share XApple launches Research app, along with three health studieshttps://pharmaphorum.com/news/apple-launches-research-app-along-with-three-health-studies/
Amarin gets FDA panel okay for new Vascepa indicationAmarin is on course to significantly increase the number of patients eligible for treatment with its purified fish Share XAmarin gets FDA panel okay for new Vascepa indicationhttps://pharmaphorum.com/news/amarin-gets-fda-panel-okay-for-new-vascepa-indication/
TMC’s inclisiran impresses at ESC, but will it surpass PCSK9 rivals?Cardiologists only had to wait a few days after The Medicines Company teased top-line results with its cholesterol-lowering Share XTMC’s inclisiran impresses at ESC, but will it surpass PCSK9 rivals?https://pharmaphorum.com/news/tmcs-inclisiran-impresses-at-esc-but-will-it-surpass-pcsk9-rivals/
Despite trial miss, Novartis still believes in Entresto for HFpEFNovartis was expecting a lot from its PARAGON-HF trial of Entresto in heart failure with preserved ejection fraction Share XDespite trial miss, Novartis still believes in Entresto for HFpEFhttps://pharmaphorum.com/news/despite-trial-miss-novartis-still-believes-in-entresto-for-hfpef/
NICE lowers threshold for blood pressure drugs in new guidanceNew guidelines on the management of high blood pressure in the UK will see thousands more patients eligible Share XNICE lowers threshold for blood pressure drugs in new guidancehttps://pharmaphorum.com/news/nice-lowers-threshold-for-blood-pressure-drugs-in-new-guidance/
Low-cost polypill could dramatically cut heart attacks, strokesA single tablet that contains four generically-available drugs – or ‘polypill’ – could offer an effective, low-cost way Share XLow-cost polypill could dramatically cut heart attacks, strokeshttps://pharmaphorum.com/news/low-cost-polypill-could-dramatically-cut-heart-attacks-strokes/
FDA clears Bayer’s Gadavist as first contrast agent for cardiac MRIBayer’s Gadavist has become the first imaging agent approved in the US to detect blockages in the hearts Share XFDA clears Bayer’s Gadavist as first contrast agent for cardiac MRIhttps://pharmaphorum.com/news/fda-clears-bayers-gadavist-as-first-contrast-agent-for-cardiac-mri/
Digital health round-up: Apple vs GoogleIs it time for Apple vs Google in healthcare? Share XDigital health round-up: Apple vs Googlehttps://pharmaphorum.com/views-and-analysis/apple-vs-google/